DSpace Общество:

Features of prepare students of pharmacy faculty for the professional pharmaceutical care in ects teaching

2014-01-01T00:00:00Z

Название: Features of prepare students of pharmacy faculty for the professional pharmaceutical care in ects teaching Авторы: Kraydashenko, O. V.; Svyntozelskyy, O. O.; Крайдашенко, Олег Вікторович; Свинтозельський, Олександр Олексійович

Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure - Relevance to Inflammatory Cytokines and Outcomes

2014-01-01T00:00:00Z

Название: Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure - Relevance to Inflammatory Cytokines and Outcomes Авторы: Berezin, A. E.; Kremzer, A. A.; Martovitskaya, Yu. V.; Березін, Олександр Євгенійович; Кремзер, Олександр Олександрович Аннотация: Aim: To evaluate the relevance of endothelial-derived apoptotic microparticles (EMPs) with inflammatory cytokine outcomes in patients with ischaemic chronic heart failure (CHF). Methods: A total of 154 patients with moderate-to-severe CHF were enrolled in the study. Flow cytometry analysis was used for quantifying the number of EMPs. All-cause mortality, CHF-related death, and CHD-readmission rates were examined. Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. Medians of circulating EMPs in survivor and non-survivor patient cohorts were 0.286 n/mL (95% CI = 0.271-0.309 n/mL) and 0.673 n/mL (95% CI = 0.65-0.74 n/mL) (P<0.001). There was a significantly lower concentration of sRANKL, OPG, TNF-alpha, sFAS, and sFAS ligand in the survivor patients when compared with those who met composed endpoints. The sFAS/sFAS ligand ratio in the non-survivor patient cohort was significantly higher than in the survivor cohort (P<0.001). In multivariate model EPMs, NYHA class, NT-pro-BNP, TNF-alpha, sFAS/sFAS ligand ratio, and OPG remained statistically significant for the cumulative endpoint: all-cause mortality, CHF-related death, and CHF-related readmission. Conclusion: Increased apoptotic circulating EMPs, OPG, and FAS-sFAS ligand ratio independently predicted cumulative survival in CHF patients.

Викладання основ косметології студентам фармацевтичного факультету

2014-01-01T00:00:00Z

Название: Викладання основ косметології студентам фармацевтичного факультету Авторы: Резніченко, Наталія Юріївна; Головкін, Анатолій Вячеславович; Веретельник, Олександр Володимирович; Красько, Микола Петрович; Лісницький, О. А.; Reznichenko, N. Yu.; Golovkin, A. V.; Veretelnyk, O. V.; Krasko, M. P.; Lesnitsky, O. A. Аннотация: Сформульовані основні принципи викладання косметології студентам фармацевтичного факультету з маніпуляційної техніки; акцент зроблено на певну тематику, що має практичне значення в роботі провізора-косметолога. The main principles of cosmetology education for students of pharmaceutical faculty relating to the manipulation technique have been stated. The main themes, which are important in cosmetology practice, have been given.

A phase II, randomized, placebo-controlled, double-blind, multi-dosestudy of SRT2104, a SIRT1activator, in subjects withtype 2 diabetes

2014-01-01T00:00:00Z

Название: A phase II, randomized, placebo-controlled, double-blind, multi-dosestudy of SRT2104, a SIRT1activator, in subjects withtype 2 diabetes Авторы: Baksi, A.; Kraydashenko, O. V.; Zalevkaya, A.; Stets, R.; Elliott, P.; Haddad, J.; Hoffmann, E.; Vlasuk, G. P.; Jacobson, E. W.; Крайдашенко, Олег Вікторович Аннотация: AIM SRT2104 is a selective activator of SIRT1. In animal models, SRT2104 improves glucose homeostasis and increases insulin sensitivity. We evaluated the tolerability and pharmacokinetics of SRT2104, and its effects on glycaemic control, in adults with type 2 diabetes mellitus. METHOD Type 2 diabetics with glycosylated haemoglobin (HbA1c) ≥ 7.5% and ≤10.5%, fasting glucose ≥160 and ≤240 mg dl−1, and on stable doses of metformin were evenly randomized to placebo or SRT2104 0.25 g, 0.5 g, 1.0 g or 2.0 g, administered orally once daily for 28 days. Changes in fasting and post-prandial glucose and insulin were analyzed. RESULTS Safety evaluation found no major differences between groups in the frequency of adverse events. SRT2104 concentrations did not increase in a dose-proportional fashion. Significant variability in exposure was observed. Treatment with SRT2104 did not lead to any consistent, dose-related changes in glucose or insulin. Day 28 change from baseline (mean (SD)): fasting glucose (mmol l−1) = −1.17 (2.42), −1.11 (3.45), −0.52 (2.60), −0.97 (2.83) and −0.15 (2.38) for placebo, 0.25 g, 0.5 g, 1.0 g and 2.0 g, respectively. Day 28 change from baseline (mean (SD)): fasting insulin (mmol l−1) = 1.0 (51.66), 8.9 (95.04), −6.9 (41.45), 4.1 (57.16) and 15.2 (138.79) for placebo, 0.25 g, 0.5 g, 1.0 g and 2.0 g, respectively) Treatment with SRT2104 was associated with improvement in lipid profiles. CONCLUSION Treatment with SRT2104 for 28 days did not result in improved glucose or insulin control which is likely due to the observed pharmacokinetics which were not dose proportional and had large between subject variability.